Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and Human Epidermal Growth factor Receptor2(HER2/neu) in Endometrial carcinoma and their correlation with histopathological type, grade and stage

Authors

  • Foujia Sharmin Department of Gynecologic Oncology, National Institute of Cancer Research and Hospital, Mohakhali, Dhaka, Bangladesh
  • Dilruba Yeasmin Department of Gynecologic Oncology, National Institute of Cancer Research and Hospital, Mohakhali, Dhaka, Bangladesh
  • Silvia Hossain Department of Gynecologic Oncology, National Institute of Cancer Research and Hospital, Mohakhali, Dhaka, Bangladesh
  • Ayesha Siddiqua Department of Gynecologic Oncology, National Institute of Cancer Research and Hospital, Mohakhali, Dhaka, Bangladesh
  • Abu Bakar Siddique Department of Radiology and Imaging, National Gastroliver Institute & Hospital, Mohakhali, Dhaka, Bangladesh.

DOI:

https://doi.org/10.3329/bmrcb.v51i1.81695

Keywords:

Endometrial carcinoma, Estrogen receptor, Progesterone receptor, Human Epidermal Growth factor Receptor2, Hormone therapy.

Abstract

Background: Endometrial carcinoma is influenced by estrogen and progesterone, with their receptors playing pivotal roles in tumor pathogenesis and therapeutic response.

Objective:  Hormonal receptor expression is linked to tumor differentiation and response to hormone therapy. This study aimed to evaluate the expression of estrogen receptors (ER), progesterone receptors (PR), and HER2/neu in endometrial carcinoma and their correlations with histological type, grade, and FIGO stage, identifying patients potentially benefiting from hormone therapy.

Methods: This cross-sectional study included 31 histologically confirmed cases of endometrial carcinoma. Clinicopathological data were collected, and immunohistochemistry was performed to assess ER, PR, and HER2/neu expression. Statistical tests were used to evaluate associations with tumor characteristics and disease staging.

Results: The mean age of patients was 57.87 ± 8.91 years, with 45.2% aged ≥60 years. Postmenopausal bleeding (80.6%) was the most common symptom, and diabetes mellitus (83.9%) and hypertension (48.4%) were frequent comorbidities. Endometrioid adenocarcinoma (58.06%) was the most common subtype, and deep myometrial invasion was observed in 54.8%. ER and PR positivity rates were 51.6% and 48.4%, respectively, with significant co-expression (p < 0.001). Both markers were strongly associated with type I and grade 2 tumors but showed no significant correlation with FIGO stage. HER2/neu expression was rare (3.2%).

Conclusion: ER and PR expression were significantly associated with favorable histological types and grades, suggesting their potential as biomarkers for hormone therapy in endometrial carcinoma. Further studies with larger cohorts are recommended to validate these findings.

Bangladesh Medical Res Counc Bull 2025;51(1):39-45

Downloads

Download data is not yet available.
Abstract
0
PDF
0

Downloads

Published

2025-09-01

How to Cite

Sharmin, F., Yeasmin, D., Hossain, S., Siddiqua, A., & Siddique, A. B. (2025). Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and Human Epidermal Growth factor Receptor2(HER2/neu) in Endometrial carcinoma and their correlation with histopathological type, grade and stage. Bangladesh Medical Research Council Bulletin, 51(1), 39–45. https://doi.org/10.3329/bmrcb.v51i1.81695

Issue

Vol. 51 No. 1 (2025)

Section

Research Papers

License

Copyright (c) 2025 Foujia Sharmin, Dilruba Yeasmin, Silvia Hossain, Ayesha Siddiqua, Abu Bakar Siddique

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms.

Authors retain copyright and grant the journal right of first publication.

Creative Commons Licence
Articles in the Bangladesh Medical Research Council Bulletin are licensed under a Creative Commons Attribution 4.0 International License (CC-BY) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).